Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

NCT02724540 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT02724540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02724540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
November 8, 2024
Enrollment
162 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, neuroendocrine tumor, malignant